Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Publications for Preeyaporn Srasuebkul Publications for Preeyaporn Srasuebkul 2016 Langton, J., Reeve, R., Srasuebkul, P., Haas, M., Viney, R., Currow, D., Pearson, S. (2016). Health service use and costs in the last 6 months of life in elderly decedents with a history of cancer: A comprehensive analysis from a health payer perspective. British Journal of Cancer, 114(11), 1293-1302. <a href="http://dx.doi.org/10.1038/bjc.2016.75">[M ore Information]</a> Parkinson, B., Viney, R., Haas, M., Goodall, S., Srasuebkul, P., Pearson, S. (2016). Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer. PharmacoEconomics, 34(10), 1039-1050. <a href="http://dx.doi.org/10.1007/s40273-016-041 1-2">[More Information]</a> 2015 Pearson, S., Abrahamowicz, M., Srasuebkul, P., Buckley, N. (2015). Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiology and Drug Safety, 24(6), 600-609. <a href="http://dx.doi.org/10.1002/pds.3753">[Mor e Information]</a> Pearce, A., Haas, M., Viney, R., Haywood, P., Pearson, S., Van Gool, K., Srasuebkul, P., Ward, R. (2015). Can administrative data be used to measure chemotherapy side effects? Expert Review of Pharmacoeconomics and Outcomes Research, 15(2), 215-222. <a href="http://dx.doi.org/10.1586/14737167.2015. 990888">[More Information]</a> Langton, J., Srasuebkul, P., Reeve, R., Parkinson, B., Gu, Y., Buckley, N., Haas, M., Viney, R., Pearson, S. (2015). Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents. Implementation Science, 10(1), 1-14. <a href="http://dx.doi.org/10.1186/s13012-014-014 8-2">[More Information]</a> Lu, C., Srasuebkul, P., Drew, A., Chen, K., Ward, R., Pearson, S. (2013). Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function? The Breast, 22(4), 482-487. <a href="http://dx.doi.org/10.1016/j.breast.2013.04. 011">[More Information]</a> 2012 Lu, C., Srasuebkul, P., Drew, A., Ward, R., Pearson, S. (2012). Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Internal Medicine Journal, 42(11), 1229-1235. <a href="http://dx.doi.org/10.1111/j.1445-5994.201 1.02604.x">[More Information]</a> 2010 Hansudewechakul, R., Sirisanthana, V., Kurniati, N., Puthanakit, T., Lumbiganon, P., Saphonn, V., Yusoff, N., Kumarasamy, N., Fong, S., Nallusamy, R., et al (2010). Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 55(4), 503-509. <a href="http://dx.doi.org/10.1097/QAI.0b013e318 1f5379a">[More Information]</a> Puls, R., Srasuebkul, P., Petoumenos, K., Boesecke, C., Duncombe, C., Belloso, W., Molina, J., Li, L., Avihingsanon, A., Gazzard, B., et al (2010). Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clinical Infectious Diseases, 51(7), 855-864. <a href="http://dx.doi.org/10.1086/656363">[More Information]</a> Srasuebkul, P., Pearson, S., Harris, C., Ward, R., Dobbins, T. (2010). The impact of oestrogen receptor (ER) status on overall survival of metastatic breast cancer patients receiving trastuzumab in Australia. 16th Annual Japanese Society for Pharmacoepidemiology Meeting and the 5th Annual Asian Conference on Pharmacoepidemiology, Japan: ACPE. 2009 Srasuebkul, P., Dobbins, T., Pearson, S. (2014). Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data. Asia-Pacific Journal of Clinical Oncology, 10(2), e63-e68. <a href="http://dx.doi.org/10.1111/ajco.12015">[M ore Information]</a> Pujari, S., Srasuebkul, P., Sungkanuparph, S., Lim, P., Kumarasamy, N., Chuah, J., Kumar, R., Chen, Y., Oka, S., Choi, J., et al (2009). Patient characteristics and treatment outcome associated with Protease Inhibitor (PI) use in the Asia-Pacific region. Journal of Antivirals and Antiretrovirals, 1(1), 28-35. <a href="http://dx.doi.org/10.4172/jaa.1000004">[ More Information]</a> 2013 Srasuebkul, P., Sungkanuparph, S., Lim, P., Law, 2014 Publications for Preeyaporn Srasuebkul M. (2009). Reply to DiNubile. Clinical Infectious Diseases, 49(5), 811-812. <a href="http://dx.doi.org/10.1086/605290">[More Information]</a> content in patients switched from failed nucleoside analogue therapy to retonavir-boosted indinavir and efavirenz. The Journal of Infectious Diseases, 194(5), 642-650. Srasuebkul, P., Lim, P., Lee, M., Kumarasamy, N., Zhou, J., Sirisanthana, T., Li, P., Kamarulzaman, A., Oka, S., Phanuphak, P., et al (2009). Short Term Clinical Disease Progression in HIV Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases, 48(7), 940-950. <a href="http://dx.doi.org/10.1086/597354">[More Information]</a> Nuesch, R., Srasuebkul, P., Ananworanich, J., Ruxrungtham, K., Phanuphak, P., Duncombe, C. (2006). Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. Journal of Antimicrobial Chemotherapy, 58(3), 637-644. <a href="http://dx.doi.org/10.1093/jac/dkl313">[Mo re Information]</a> 2008 Nuesch, R., Ananworanich, J., Srasuebkul, P., Chetchotisakd, P., Prasithsirikul, W., Klinbuayam, W., Mahanontharit, A., Juppimai, T., Ruxrungtham, K., Hirschel, B. (2008). Interruptions of tenofovir/emtricitabine based ART in patients with HIV/HBV co-infection. AIDS, 22(1), 152-154. <a href="http://dx.doi.org/10.1097/QAD.0b013e328 2f303bf">[More Information]</a> 2007 Srasuebkul, P., Calmy, A., Zhou, J., Kumarasamy, N., Law, M., Lim, P. (2007). Impact of drug classes and threatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Databade (TAHOD). AIDS Research and Therapy, 4(18), 1-10. <a href="http://dx.doi.org/10.1186/1742-6405-4-18" >[More Information]</a> Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54. 2006 Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., Ubolyam, S., Burger, D., Reiss, P., Stek Jr, M., et al (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232. Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., Wangsuphachart, S., Krisanachinda, A., Lerdlum, S., Lange, J., et al (2006). Changes in body composition and mitochondrial nucleic acid Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek Jr, M., Lange, J., Phanuphak, P., Cooper, D., Udomuksorn, W., et al (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmocogenet Genomics, 16(5), 321-329. <a href="http://dx.doi.org/10.1097/01.fpc.00001974 65.14340.d4">[More Information]</a> 2005 Cardiello, P., Hassink, E., Ananworanich, J., Srasuebkul, P., Samor, T., Mahanontharit, A., Ruxrungtham, K., Hirschel, B., Lange, J., Phanuphak, P., et al (2005). A propspective, randomised trial of structured treatment interruption for patients with chronic HIV Type 1 infection. Clinical Infectious Diseases, 40(4), 594-560. Srasuebkul, P. (2005). Parametric models to predict immunological failure in Thai patients receiving Antiretroviral therapy. Australasia society for HIV medicine conference 2005, Hobart: ASHM - Australasian Society for HIV Medicine. Cardiello, P., Srasuebkul, P., Hassink, E., Mahanontharit, A., Samor, T., Ruxrungtham, K., Lange, J., Cooper, D., Phanuphak, P. (2005). The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Medicine, 6(2), 122-128. 2004 Ungsedhapand, C., Srasuebkul, P., Cardiello, P., Ruxrungtham, K., Ratanasuwan, W., Kroon, E., Tongtalung, M., Juengprasert, N., Ubolyam, S., Siangphoe, U., et al (2004). Three-year durability of dual-nucleoside therapy in a Thai population with HIV infection. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 36(2), 693-701. <a href="http://dx.doi.org/10.1097/00126334-20040 6010-00006">[More Information]</a> Publications for Preeyaporn Srasuebkul 2003 Ananworanich, J., Nuesch, R., Teeratakulpisarn, S., Srasuebkul, P., Chuenyam, T., Siangphoe, U., Ungsedhaphand, C., Phanuphak, P., Ruxrungtham, K. (2003). In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 32(5), 570-572. 2002 Pothikamjorn, S., Ruxrungtham, K., Thampanitchawong, P., Fuangthong, R., Srasuebkul, P., sangahsapaviriyah, A., Suttithavil, W., Klaewsongkram, J., Parisuthikul, V., Viravan, T., et al (2002). Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function. Asian Pacific Journal of Allergy and Immunology, 20(2), 77-83. Cardiello, P., van Heeswijk, R., Hassink, E., Srasuebkul, P., Mahanontharit, A., Samor, T., Worarien, W., Beijnen, J., Hoetelmans, R., Ruxrungtham, K., et al (2002). Simplifying protease inhibitor therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100mg): HIVNAT 001.3 Study. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 29(5), 464-470. 2001 Srasuebkul, P. (2001). The Long-term efficacy of saquinavir-soft gelatin capsules plus either Combivir (AZT/3TC) or ddl/d4T in HIV1+ Thai patients pretreated with AZT/ddC: HIV-NAT 001.1 and 001.2. Royal College of Physicians of Thailand Meeting 2001, Thailand: Royal College of Physicians of Thailand.